Trial · NCT02287311

Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)

NCT02287311, Phase 1, Active not recruiting, Baylor College of Medicine; results first posted 2025-02-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL). Trials, record NCT02287311. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02287311

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
NCT number: NCT02287311
Status: Active not recruiting
Phases: Phase 1
Enrollment: 38 participants, actual
Lead sponsor: Baylor College of Medicine
Conditions: Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease, Nasopharyngeal Carcinoma, Smooth Muscle Tumor
Interventions: MABEL CTLs, Cyclophosphamide, Fludarabine
First posted: 2014-11-10
Last updated: 2026-03-23
Results first posted: 2025-02-24

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With a Dose-limiting Toxicity (DLT)	8 weeks	To evaluate the safety of administering escalating doses of banked allogeneic, partially HLA-matched rapid EBV specific T cells.
Secondary	Percent of Patients Whose Best Response is Either Complete Remission or Partial Remission	8 weeks	To measure anti-tumor and anti-viral effects of ESTs

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With a Dose-limiting Toxicity (DLT)	8 weeks	All DLT evaluable participants were included in the analysis. DLT evaluable refers to participants who received two infusions and either completed the 8 weeks toxicity evaluation period without experiencing a DLT or developed a DLT during this period. Ten participants were not evaluable for DLT and were excluded from the analysis, including one participant who was later re-enrolled and became evaluable for DLT at the 2nd enrollment.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Percent of Patients Whose Best Response is Either Complete Remission or Partial Remission	8 weeks	All response evaluable participants were included in the analysis. Participants who received the first infusion were evaluable for response, except those who received chemotherapy between the first and second infusions. Two participants were not evaluable for response and were excluded from the analysis. The participant who enrolled twice was counted as 2 individuals but was only evaluable for response at the 2nd enrollment.	percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Number of Participants With a Dose-limiting Toxicity (DLT)	Group A Cohort 1	0		Participants
Number of Participants With a Dose-limiting Toxicity (DLT)	Group A Cohort 2	0		Participants
Number of Participants With a Dose-limiting Toxicity (DLT)	Group A Cohort 3	0		Participants
Number of Participants With a Dose-limiting Toxicity (DLT)	Group B Cohort 1	0		Participants
Number of Participants With a Dose-limiting Toxicity (DLT)	Group B Cohort 2	0		Participants
Number of Participants With a Dose-limiting Toxicity (DLT)	Group B Cohort 3	0		Participants
Number of Participants With a Dose-limiting Toxicity (DLT)	Group C Cohort 1	0		Participants
Number of Participants With a Dose-limiting Toxicity (DLT)	Group C Cohort 2	0		Participants
Number of Participants With a Dose-limiting Toxicity (DLT)	Group C Cohort 3	0		Participants
Percent of Patients Whose Best Response is Either Complete Remission or Partial Remission	Group A Cohort 1	0.0	95% Confidence Interval 0.0 to 84.2	percentage of participants

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow81

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Cohort 1: Dose Level 1	STARTED	Group A Cohort 1	3
Cohort 1: Dose Level 1	STARTED	Group A Cohort 2	0
Cohort 1: Dose Level 1	STARTED	Group A Cohort 3	0
Cohort 1: Dose Level 1	STARTED	Group B Cohort 1	5
Cohort 1: Dose Level 1	STARTED	Group B Cohort 2	0
Cohort 1: Dose Level 1	STARTED	Group B Cohort 3	0
Cohort 1: Dose Level 1	STARTED	Group C Cohort 1	2
Cohort 1: Dose Level 1	STARTED	Group C Cohort 2	0
Cohort 1: Dose Level 1	STARTED	Group C Cohort 3	0
Cohort 1: Dose Level 1	COMPLETED	Group A Cohort 1	0

1 to 10 of 81Source ClinicalTrials.gov

See all 81 participant flow

Adverse events1,476

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	Group A Cohort 1	1	3	1
other	Anemia	Blood and lymphatic system disorders	Group A Cohort 2	2	3	3
other	Anemia	Blood and lymphatic system disorders	Group A Cohort 3	4	6	4
other	Anemia	Blood and lymphatic system disorders	Group B Cohort 1	2	5	6
other	Anemia	Blood and lymphatic system disorders	Group B Cohort 2	1	3	1
other	Anemia	Blood and lymphatic system disorders	Group B Cohort 3	1	7	1
other	Anemia	Blood and lymphatic system disorders	Group C Cohort 1	1	2	1
other	Anemia	Blood and lymphatic system disorders	Group C Cohort 2	3	4	3
other	Anemia	Blood and lymphatic system disorders	Group C Cohort 3	0	3	0
other	Blood and lymphatic system disorders - Other, specify : Thrombocytopenia	Blood and lymphatic system disorders	Group A Cohort 1	0	3	0

1 to 10 of 1,476Source ClinicalTrials.gov

See all 1,476 adverse events

Adverse event totals27

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Group A Cohort 1	2	3
Total, all-cause mortality	Group A Cohort 2	2	3
Total, all-cause mortality	Group A Cohort 3	4	6
Total, all-cause mortality	Group B Cohort 1	3	5
Total, all-cause mortality	Group B Cohort 2	2	3
Total, all-cause mortality	Group B Cohort 3	4	7
Total, all-cause mortality	Group C Cohort 1	1	2
Total, all-cause mortality	Group C Cohort 2	2	4
Total, all-cause mortality	Group C Cohort 3	2	3
Total, other adverse events	Group A Cohort 1	3	3

1 to 10 of 27Source ClinicalTrials.gov

See all 27 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02287311

GET https://conductscience.org/api/trials/v1/NCT02287311/flow?page=2

API reference For AI assistants